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ABSTRACT
The use of magnetic nanoparticles (MNPs) in drug delivery vehicles must address issues such as drug-
loading capacity, desired release profile, aqueous dispersion stability, biocompatibility with cells and 
tissue, and retention of magnetic properties after interaction with macromolecules or modification 
via chemical reactions. Amphotericin B (AmB) is still the first choice for the treatment of severe 
paracoccidioidomycosis, an important systemic fungal infection caused by Paracoccidoides brasiliensis. 
Unfortunately, AmB causes acute side effects (mainly urinary problems) following intravenous 
administration, which limits its clinical use. The use of magnetic nanoparticles stabilized with 
biocompatible substances, together with the possibility of their conjugation with drugs has become a new 
nanotechnological strategy in the treatment of diseases for drug delivery to specific locations, such as the 
lungs in paracoccidoidiodomycosis. This review provides an overview of the disease, its etiologic agent 
and treatment with emphasis on the main strategies to improve the use of AmB in nanoformulations. 
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RESUMEN
El uso de nanopartículas magnéticas (MNPS) en los vehículos de suministro de fármacos debe abordar cuestiones 
como la capacidad de carga de las drogas, el perfil deseado de liberación, estabilidad de la dispersión acuosa, 
biocompatibilidad con las células, tejidos y la conservación o la modificación de las propiedades magnéticas 
después de la interacción con macromoléculas y/o reacciones químicas. La anfotericina B (AnB) continua siendo la 
primera opción para el tratamiento de la paracoccidioidomicosis grave, una importante infección sistémica causada 
por el hongo Paracoccidoides brasiliensis. Sin embargo, la AnB causa efectos secundarios agudos (principalmente 
problemas urinarios) tras la administración intravenosa, limitando su uso clínico. El uso de nanopartículas 
magnéticas estabilizadas con sustancias biocompatibles y conjugadas con fármacos, se ha convertido en una 
nueva estrategia nanotecnológica para el tratamiento de enfermedades en sitios específicos, como los pulmones en 
paracoccidoidiodomycosis. En esta revisión se hace una descripción general de la enfermedad, su agente etiológico 
y su tratamiento con énfasis en la principales estrategias para mejorar el uso de AnB en nanoformulaciones.
Palabras clave: Paracoccidioides brasiliensis, anfotericina B, nanoparticulas de magnetita; fluido magnético; 
entrega controlada de medicamentos 
Introduction
The paracoccidioidomycosis (PCM) is a systemic 
mycosis autochthonous from South and Central America, 
endemic in rural populations, but with heterogeneous 
distribution (with low and high endemicity).
Figure 1.  Geographical distribution of paracoccidioidomycosis 
(adapted from Shikanai-Yasuda et al., 2006)
This mycosis affects mainly men between 30 and 60 
years old. It is believed that 50% of the inhabitants 
of endemic areas in countries such as Venezuela, 
Colombia, Argentina and Brazil have been exposed to 
the etiologic agent of this mycosis. However, only 2% 
of individuals develop some clinical manifestation of 
the disease 1,2. It is noteworthy that when not diagnosed 
and treated appropriately, the PCM can disseminate 
affecting progressively the lungs, and may reach other 
organs. Even if the patient presents improvements due 
to the treatment, it can develop pulmonary fibrosis, the 
most serious sequel resulting from lung granulomatous 
processes, leading to limitations of the individual 
activities 3. 
The etiologic agent of the PCM is Paracoccidioides 
brasiliensis, a saprobiotic fungus that in nature presents 
itself as filamentous between 25 ºC and 30 ºC, i.e. a 
multicellular mycelium containing propagules called 
conidia infectors. Once inhaled by mammals, the 
propagules turn into yeast forms of fungus that will be 
their parasitic form in host tissues, thus behaving as a 
thermo-dimorphic fungus 1,4. 
Treatment of paracoccidioidomycosis
Unlike other pathogenic fungi, the P. brasiliensis is 
sensitive to most antifungal drugs therefore various 
antifungal agents are used in the treatment of PCM 5. 
The choice of drug to be used is in accordance with the 
state of the patient, and requires, besides a long period 
of treatment, patient monitoring in order to evaluate the 
efficacy and his tolerance to the antifungal 6. Among 
the most popular drugs, stand out Itraconazole and 
Amphotericin B 1.
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Figure 2. Chemical structure of the drug amphotericin B. 
Adapted from Carrillo-Muñoz et al., 2006.
Amphotericin B is a polyene antibiotic and is produced 
by the actinomycete Streptomyces nodosus. It has been 
the drug of choice for the treatment of most systemic 
mycoses 7,8.
AmB mechanism of action occurs by its hydrophobic 
interaction with ergosterol, the most abundant sterol 
in P. brasiliensis cell membranes. These interactions 
induce the formation of aqueous pores in the fungi 
membranes and thus triggering death 9,10. Although 
Amphotericin B preferentially binds to the ergosterol, it 
can also bind to cholesterol11, the most abundant sterol 
founded in mammals’ cells membranes 9,12, and for that 
reason its administration in humans must be controlled. 
This drug has broad-spectrum antifungal action, potent 
fungicidal activity and rare episodes of resistance, 
which contributes to the clinical success of this drug13. 
Nevertheless, AmB induces severe side effects in humans 
and is considered one of the most toxic antibiotics for 
humans7,13, often leading to patient hospitalization 
during the administration of this drug for adequate 
monitoring 1,14,15. The most frequent side effects are 
nausea, vomiting, fever, headache, hypotension, liver 
damage, anemia and especially nephrotoxicity 7,13. 
The incidence of nephrotoxicity induced by AmB is very 
high, affecting 49 to 65% of the patients 16. Nephrotoxicity 
is due to the binding of AmB to cholesterol in the 
nephron convoluted tubules cell membranes14,15,17, 
creating an ion channel in these membranes that allows 
the flow of ions and small intracellular molecules. 
When these ions exit, especially potassium, impairment 
of cell metabolism occurs 18. The accumulation of 
potassium ions in the blood, hyperkalemia, can induce 
severe cardiac arrhythmia 19. The serum levels of the 
drug contribute to increase such toxicological effects, 
since the greater the amount of free flowing drug, more 
damage will cause to the kidneys. Nephrotoxicity is the 
cause of prolonged hospitalization and mortality rates, 
especially in patients requiring hemodialysis.
In order to reduce the adverse effects of Amphotericin 
B in treatment of PCM, new strategies are being 
developed in the formulation of this drug, specially 
using nanotechnology.
Nanotechnology as a tool for drug delivery
Nanotechnology is referred as the manipulation of 
matter with at least one dimension sized from 1 to 100 
nanometers. Nanobiotechnology is the science that 
investigates the interactions between those nanoscale 
materials and biological systems. Thus, nanostructured 
materials, nanoparticles in particular, exhibit new 
thermal, mechanical, magnetic and optical properties 
such as small size, large surface area to mass ratio, and 
high reactivity delivery, that allow for their widespread 
application in biomedicine and many industrial sectors 20.
A major contribution of nanobiotechnology for new 
formulations of conventional drugs is the possibility 
of creating functional systems of drug delivery at the 
nanoscale so that their kinetic properties and dynamics 
can be modified to optimize its pharmacological 
response 21. Among the benefits of a nanoscale system 
for drug delivery is the bioavailability enhancement 
of associated drugs and/or improvement of drugs 
distribution and targeting in tissues. This controlled 
drug delivery allows decreasing in the number of drug 
applications in patients, and also reduces nanoparticle 
uptake by the reticuloendothelial system (RES).
Nanoparticles are typically defined as solids with less 
than 100 nm in all three dimensions. Most often, they 
are particles having diameters about 10 nm or less 
and this size is similar to most biological molecules 
and structures 22. Thereby, nanoparticles can be 
useful in biomedical research and applications. Some 
nanoparticles commonly consist of magnetic elements 
such as iron, nickel and cobalt and their chemical 
compounds.  These nanoparticles can be synthesized 
and modified with various chemical functional groups 
and conjugated with biological molecules or structures, 
such as drugs of interest, opening a wide range of 
potential applications in biomedicine 20. Metal and 
magnetic nanoparticles have been continuously used 
and modified to enable their use as a drug delivery 
system.
It is worth mentioning that liposomes also are used in 
drug delivery. Liposomes are spherical vesicles made 
from phospholipids bilayer. Thus lipid-soluble drugs 
can be incorporated into their lipid phase, whereas 
water-soluble drugs can be entrapped into their aqueous 
phase. Their advantage is the easily manufacture 
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process, they are no covalent aggregates, have almost 
no toxicity, biodegradable, among others. Therefore, 
nanoparticles and liposomes can be applied to facilitate 
the administration of antimicrobial drugs, thereby 
overcoming some of the limitations in traditional 
antimicrobial therapeutics. According to Zhang et al, 
antimicrobial drugs encapsulation enhances therapeutic 
effectiveness and minimizes side effects of the drugs 23. 
Antimicrobial drug associated to metal 
nanoparticles
Metal nanoparticles exhibit excellent bactericidal action 
against Gram-positive and Gram-negative bacteria. 
This effect has been attributed to small size and high 
surface to volume ratio, which allows them to interact 
closely with microbial membranes and is not merely 
due to the release of metal ions in solution 24. Silver 
nanoparticles (AgNPs), for example, have the ability 
to anchor to the bacterial cell wall and subsequently 
penetrate it, thereby causing structural changes, like the 
permeability, in the membrane and cell death 25. Thus, 
AgNPs can kill antibiotic-resistant microbes. Several 
studies have demonstrated antimicrobial effects of silver 
nanoparticles against Escherichia coli, Staphylococcus 
aureus, Salmonella typhimurium, Pseudomonas 
aeruginosa, Bacillus subtilis and yeast strains 26-29. It 
is noteworthy that AgNPs exhibited no antibacterial 
activity in the presence of serum proteins. However, as 
demonstrated by Gnanadhas and co-workers  AgNPs 
capped with citrate or poly (vinylpyrrolidone) exhibited 
antibacterial activities in vivo against Salmonella 
infection compared to uncapped AgNPs 30. It is worth 
mentioning that there are numerous consumer products 
utilizing the antimicrobial properties of AgNPs, such as 
cosmetics, water filters, and food packaging containers.
Although the most common metal nanoparticles used as 
the antimicrobial agent are AgNPs, gold nanoparticles 
(AuNPs) are being used effectively against strains 
of Gram-positive and Gram-negative bacteria like 
Micrococcus luteus, Pseudomonas aeruginosa 
Escherichia coli and Staphylococcus aureus. It also 
exhibit antifungal activity against Aspergillus niger and 
Fusarium oxysporum 31. Additionally AuNPs dispersed 
on zeolites eliminate Escherichia coli and Salmonella 
typhi in 90 minutes 32.The authors showed that AgNP 
were intrinsically antibacterial, whereas AuNP were 
antimicrobial only when ampicillin was bound to their 
surface. The antimicrobial activity of AuNPs can be 
attributed to the ability of interaction with functional 
groups on bacterial cell and inactive bacteria; it cause 
structural changes, degradation and cell death 33. 
Furthermore AuNPs also may act as drug carriers34. 
Antimicrobial tests have also shown that copper 
nanoparticles can have antimicrobial activity; surfaces 
of the copper nanoparticles interact directly with 
the outer bacterial membrane causing it to rupture 
and thus killing bacteria 24. The authors clearly 
demonstrated that copper nanoparticles synthesized 
in green synthesis method exhibit more antibacterial 
activity against Escherichia coli than copper sulphate 
solution and pure ginger extract. The encapsulation of 
antimicrobial drugs in nanoparticle systems enhances 
therapeutic effectiveness and minimizes side effects of 
antimicrobial agents.
Magnetic nanoparticles and antimicrobial 
activity
Magnetic nanoparticles (MNPs) commonly consist 
of magnetic elements such as iron, nickel, cobalt 
and manganese or zinc, and most often by ferrite as 
magnetite (Fe3O4) or maghemite (γ-Fe2O3) 
35. Such 
nanoparticles when dispersed in colloidal solutions 
constituted magnetic fluids (MFs), stable suspensions 
of magnetic nanoparticles with a diameter generally 
ranging between 5 and 15 nm, in inorganic or organic 
solvent carrier. In these solutions, the particle-liquid 
interactions are strong enough that their magnetic 
behaviors are transmitted to the liquid as a whole 36. 
Magnetic nanoparticles can bind to drugs, proteins, 
enzymes, antibodies, or nucleotides and can be directed 
to an organ. Although MNPs are mostly used on cancer 
research and treatment, new antibiotic coated magnetic 
nanoparticles intended as magnetically controllable 
pharmaceutical agents for the recovery of bacteria 
loaded tissues and organs. It is reasonable to assume 
that the conjugation of antimicrobial drugs to magnetic 
nanoparticles can combine the best properties of both, 
generating an improved antimicrobial nanoparticle, and 
enhancing therapeutic effectiveness of antimicrobial 
drugs in the treatment of infectious diseases.
Antimicrobial activity of MNPs was described 
by Grumezescu and collaborators, they reveal the 
synergistic effect of the synthesized water dispersible 
magnetic nanocomposites on the activity of different 
antibiotics against Gram-positive and Gram-negative 
bacterial strains37. Similarly, Dong and co-workers 
have shown that the combination of barbituric acid-
based N-halamine with magnetic nanoparticles exhibit 
higher biocidal activity than the bulk powder barbituric 
acid-based N-halamine besides facilitates the repeated 
antibacterial applications 38. Nevertheless, magnetic 
nanoparticles are recognized by macrophages of the 
mononuclear phagocyte system and are eliminated 
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from the body. In order to improve biocompatibility, 
to reduce toxicity and to ensure non-immuno-genicity, 
particles have been encapsulated (e.g., with chitosan, 
dextran, lactic acid).
Another important factor is that it consists of iron, which 
acts to maintain the operation of essential metabolic 
pathways present in living organisms in general 39,40. For 
pathogenic microorganisms, especially P. brasiliensis, 
the ability to acquire iron is crucial for the establishment 
of infection, so that the ability to capture this element 
from the host is considered a virulence factor 41. 
Moreover, studies show that P. brasiliensis, both the 
yeast and mycelial forms, has a metabolic demand 
for iron42. Cano and colleagues demonstrated that 
the restriction of iron was one of the mechanisms by 
which inhibit the transformation of yeast in the form of 
conidia in activated macrophages, subsequently yeast 
growth within macrophages 43. Similarly, studies with 
chloroquine, a drug which affects the metabolism of 
iron in macrophages decreases the intracellular survival 
of the yeast P. brasiliensis in macrophages by interfering 
with the acquisition of iron by the fungus 44-46.
Other studies also demonstrate antimicrobial effect of 
zinc oxide (ZnO) nanoparticles. Vani et al 47 reports 
that they can be applied effectively for the control of 
microorganisms and the prevention of infections caused 
by Staphylococcus aureus. The antibacterial activity 
of ZnO nanoparticles also has been studied by Jones 
et al 48. According to the authors these nanoparticles 
have a potential application as bacteriostatic agent in 
visible light and may be used to control the spread and 
infection of a variety of bacterial strains.
Anfotericin formulations
The burden of invasive fungal infections (IFIs) has 
increased in the last years, especially from the increasing 
prevalence of individuals with immunosuppression, 
causing high morbidity and mortality, partly among ill 
patients 49,50. Amphotericin B deoxycholate (AmB-D) 
has been the cornerstone for the treatment of IFIs over 
the past four decades. Its broad-spectrum fungicidal 
activity has been showing efficient in candidiasis, 
cryptococcosis, aspergillosis, histoplasmosis, 
blastomycosis, coccidioidomycosis, zygomycosis, 
sporotrichosis, fusariosis, and phaeohyphomycosis. 
Fungi resistant to AmB are rare, including Trichosporon 
spp., Aspergillus terreus, Scedosporium spp. and 
Malassezia furfur 51.
However, as already written, conventional AmB-D 
is associated with adverse effects in 50-90% of 
cases, including acute infusion reactions, electrolyte 
imbalances, and dose-dependent nephrotoxicity 46. 
The infusion reactions are probably linked with the 
induction of pro-inflammatory cytokines demonstrated 
to be produced by AmB and the release of TNF-alpha 
from macrophages 52. Nephrotoxicity is defined in most 
studies as duplication of baseline creatinine levels. It 
is associated with vasoconstriction causing ischemic 
injury and direct interaction with epithelial cell 
membranes causing tubular dysfunction 53.
Given the above, extensive efforts were made to 
reformulate AmB in the last 15 years.  AmB has strong 
lipophilic properties that led to the encapsulation of the 
drug into lipossomes or binding to lipid complexes. 
These lipid formulations of AmB are an attempt to 
enhance efficacy by increased dosing and to improve 
the safe profile, reducing the adverse effects 52.
Three lipid formulations of AmB are licensed and 
available. They are: 1) amphotericin B lipid complex 
(ABLC), composed of amphotericin B complexed with 
two phospholipids in a 1:1 drug-to-lipid molar ratio. The 
two phospholipids, l-α-dimyristoylphosphatidylcholine 
and l-α-dimyristoylphosphatidylglycerol, are present in 
a 7:3 molar ratio. ABLC has a ribbons-shaped complex 
with length range from 1.6 to 11.1 nm. The commercial 
product is Albelcet®. 2) amphotericin B colloidal 
dispersion (ABCD), consists of a 1:1 (molar ratio) 
complex of amphotericinB and cholesteryl sulphate. 
Upon reconstitution it forms a colloidal dispersion of 
microscopic uniform disc-shaped particles with diameter 
range from 120 to 140 nm and thickness of 4 nm. The 
commercial product is Amphotec® and Amphocil®. 
3) Liposomal amphotericin B (L-AmB), consists of a 
1:9 (drug-to-lipid molar ratio) of amphotericin B with 
hydrogenated soy phosphatidylcholine, distearoyl, 
hosphatidylglycerol, cholesterol, sucrose, and 
disodium succinate hexahydrate as buffer.  It consists 
of unilamellar bilayer liposomes with amphotericin B 
intercalated within the membrane. Due to the nature 
and quantity of amphophilic substances used, and the 
lipophilic moiety in the amphotericin B molecule, the 
drug is an integral part of the overall structure of the 
liposomes. L-AmB is sphere-shaped with diameter 
range from 45 to 80 nm. The commercial product is 
Ambisome® 54,55. 
These lipid formulations differ in several aspects, 
in their lipid composition, shape, physicochemical 
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properties and pharmacokinetic parameters. They 
share different accumulation rates to various tissue 
components. 
ABLC, because of its size, is taken up rapidly by 
macrophages and becomes sequestered in tissues of 
the mononuclear phagocyte system such as the liver 
and spleen, so it has lower circulating amphotericin B 
serum concentrations when compared to AmB-D 56. 
Lung levels are considerably higher than those achieved 
with other lipid-associated preparations, suggesting 
a potential formulation for the treatment of fungal 
respiratory infections, such as paracoccidioidomycosis. 
The recommended therapeutic dose of ABLC is 5 mg/
kg/day 57.
ABCD complexes remain largely intact, after intravenous 
injection, and are rapidly removed from the circulation 
by macrophage. The peak plasma level (Cmax) achieved 
is lower than that attained by AmB-D. ABCD exhibits 
dose-limiting, infusion-related toxicities; consequently, 
the administered dosages should not exceed 3–4 mg/kg/
day 56.
L-AmB avoids substantial recognition and uptake by 
the reticuloendothelial system due to its small size and 
negative charge. Therefore, a single dose of L-AmB 
results in a much higher Cmax/MIC value than AmB-D 
and a much larger area under the concentration–time 
curve. Tissue concentrations in patients receiving L-AmB 
tend to be lower in kidneys and lung and highest in the 
liver and spleen. Recommended therapeutic dosages are 
3–6 mg/kg/day 56-58.
Wade and coworkers, in a well-designed head-to-head 
observational study, compared the nephrotoxicity and 
other adverse events among patients receiving liposomal 
amphotericin B or amphotericin B lipid complex. A total 
of 327 hospitalized patients were analyzed, they differed 
in terms of age, gender, race, and urgent/emergent 
admission status, but all of them were infected with 
Aspergillus, Candida, and/or Cryptococcus, were older 
than 18 years, with evidence of renal impairment or with 
increase risk of nephrotoxicity from AmB. They observed 
that those receiving ABLC demonstrated approximately 
threefold greater odds of developing nephrotoxicity 
compared to patients who received L-AMB, as well 
as the ABLC therapy was associated with significantly 
higher rates of infusion reactions 50.
In clinical studies it has been proved that the cost 
of treatment with lipid formulations of AmB can be 
overweighed by the cost of nephrotoxicity. Interpreting 
the findings of all studies is further complicated by 
differences in study populations with respect to age, 
disease state, infectious organism, risk factors for IFIs, 
exposure to nephrotoxic agents, and different definitions 
of nephrotoxicity 58. 
In summary, all of the lipid formulations have 
demonstrated equivalent efficacy and reduced toxicity 
compared to AmB-D, but by a mechanism that is not 
yet exactly known. It is assumed that they offer less 
free drug that is able to bind to the kidney epithelial 
cells as mammalian cells are affected only by high free 
amphotericin B concentrations.
A formulation of poly (lactic-co-glycolic acid) (PLGA) 
and dimercaptosuccinic acid (DMSA) polymeric 
nanoparticles loaded with AmB-D (Nano-AmB) was 
tested in mice infected with P. brasiliensis.  At 30 days 
post-infection, the animals were treated with Nano-AmB 
(6 mg/kg of encapsulated AmB-D, intraperitoneally (ip), 
interval of 72 h) or AmB-D (2 mg/kg, ip, interval of 24 h) 
during 30 days. Nano-AmB showed a marked antifungal 
efficacy. No renal or hepatic biochemical abnormalities, 
as well as no genotoxicity and cytotoxicity effects, 
were found in the animals treated with Nano-AmB. 
Thus, Nano-AmB comprises an AmB formulation able 
to lessen the number of drug administrations, once it 
showed a favorable extended dosing interval 59.
Alternatively, our group have been developed a new 
formulation of AmB associated with maghemite-based 
magnetic fluid stabilized with bilayer of lauric acid 
(BCL-AmB). 
Figure 3. Schematic structure of amphotericin B conjugated with 
a magnetic nanoparticle stabilized with bilayer of lauric acid. 
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It is a very stable nanomaterial (over 240 days) with 
average size value of 13 nm. BCL-AmB presented 
antifungal activity against P. brasiliensis with a higher 
MIC value compared to AmB-D, and presented no 
cytotoxicity to the human urinary cells while inducing 
low cytotoxicity to the peritoneal macrophages. In vivo 
studies showed that BCL-AmB was effective against 
the acute form of PCM experimental, but not the chronic 
infection, and did not induce clinical, biochemical and 
histolopathological alterations (Paper in preparation).
Lung tissue samples removed from P. brasiliensis-
infected and BCL-AmB treated mice were deposited 
onto Surface Enhanced Raman Scattering (SERS) 
active substrates for recording the Raman spectra. The 
results revealed spectral changes in relative intensities 
which are associated to the oxidation state of both the 
protein b588 and the myeloperoxidase enzyme, and so 
consistent with the oxygenation process of neutrophils’s 
heme groups triggered by fungal infection 60.
It is possible to consider that the fungus infection in 
animals treated with Free AmB and BCL-AmB is 
much less than in animals treated with PBS, and both 
treatments led to similar therapeutic outcomes. We 
claim that the therapeutic approach using BCL-AmB 
has advantages over the conventional one, since the 
AmB content administered in BCL-AmB is 40% lower 
than the content administered in Free AmB, and it is 
well know that adverse effects reduce as the AmB doses 
reduce also. In addition, the magnetic drug carrier (BCL-
AmB) administration was performed in intervals three-
times (72 hours) longer than free AmB (24 hours) 60. 
Therefore, it is reasonable to believe that AmB when 
coupled to magnetic nanoparticles stabilized with 
bilayer lauric acid, by having similar antifungal activity 
and do not induce adverse effects at therapeutic doses in 
acute infection and also allows reduction of the number 
of applications, can be an alternative nanotool to the 
treatment of acute form of PCM, but further studies 
must be done to improve effectiveness in chronic 
infection. 
CONCLUSION
In conclusion, the use of magnetic nanoparticles 
stabilized with biocompatible substances, together with 
the possibility of their conjugation with drugs has become 
a new nanotechnological strategy in the treatment of 
diseases for drug delivery to specific locations, such as 
the lungs in paracoccidoidiodomycosis. 
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